Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models

María Virtudes Céspedes, María José Guillén, Pedro Pablo López-Casas, Francesca Sarno, Alberto Gallardo, Patricia Álamo, Carmen Cuevas, Manuel Hidalgo, Carlos María Galmarini, Paola Allavena, Pablo Avilés, Ramón Mangues

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We explored whether the combination of lurbinectedin (PM01183) with the antimetabolite gemcitabine could result in a synergistic antitumor effect in pancreatic ductal adenocarcinoma (PDA) mouse models. We also studied the contribution of lurbinectedin to this synergism. This drug presents a dual pharmacological effect that contributes to its in vivo antitumor activity: (i) specific binding to DNA minor grooves, inhibiting active transcription and DNA repair; and (ii) specific depletion of tumor-associated macrophages (TAMs). We evaluated the in vivo antitumor activity of lurbinectedin and gemcitabine as single agents and in combination in SW-1990 and MIA PaCa-2 cell-line xenografts and in patient-derived PDA models (AVATAR). Lurbinectedin-gemcitabine combination induced a synergistic effect on both MIA PaCa-2 [combination index (CI)=0.66] and SW-1990 (CI=0.80) tumor xenografts. It also induced complete tumor remissions in four out of six patient-derived PDA xenografts. This synergism was associated with enhanced DNA damage (anti-γ- H2AX), cell cycle blockage, caspase-3 activation and apoptosis. In addition to the enhanced DNA damage, which is aconsequence of the interaction of the two drugs with the DNA, lurbinectedin induced TAM depletion leading to cytidine deaminase (CDA) downregulation in PDA tumors. This effect could, in turn, induce an increase of gemcitabine-mediated DNA damage that was especially relevant in high-density TAM tumors. These results show that lurbinectedin can be used to develop 'molecularly targeted' combination strategies.

Original languageEnglish
Pages (from-to)1461-1471
Number of pages11
JournalDMM Disease Models and Mechanisms
Volume9
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

gemcitabine
Macrophages
Tumors
Adenocarcinoma
DNA
Neoplasms
Heterografts
DNA Damage
Cytidine Deaminase
Antimetabolites
Transcription
Drug Interactions
Caspase 3
DNA Repair
Pharmaceutical Preparations
Cell Cycle
Repair
Down-Regulation
Chemical activation
Cells

Keywords

  • Gemcitabine
  • Lurbinectedin
  • PDA mouse models
  • Synergism
  • Tumor-associated macrophage depletion

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Medicine (miscellaneous)
  • Immunology and Microbiology (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models. / Céspedes, María Virtudes; Guillén, María José; López-Casas, Pedro Pablo; Sarno, Francesca; Gallardo, Alberto; Álamo, Patricia; Cuevas, Carmen; Hidalgo, Manuel; Galmarini, Carlos María; Allavena, Paola; Avilés, Pablo; Mangues, Ramón.

In: DMM Disease Models and Mechanisms, Vol. 9, No. 12, 01.12.2016, p. 1461-1471.

Research output: Contribution to journalArticle

Céspedes, MV, Guillén, MJ, López-Casas, PP, Sarno, F, Gallardo, A, Álamo, P, Cuevas, C, Hidalgo, M, Galmarini, CM, Allavena, P, Avilés, P & Mangues, R 2016, 'Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models', DMM Disease Models and Mechanisms, vol. 9, no. 12, pp. 1461-1471. https://doi.org/10.1242/dmm.026369
Céspedes, María Virtudes ; Guillén, María José ; López-Casas, Pedro Pablo ; Sarno, Francesca ; Gallardo, Alberto ; Álamo, Patricia ; Cuevas, Carmen ; Hidalgo, Manuel ; Galmarini, Carlos María ; Allavena, Paola ; Avilés, Pablo ; Mangues, Ramón. / Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models. In: DMM Disease Models and Mechanisms. 2016 ; Vol. 9, No. 12. pp. 1461-1471.
@article{52f92a20ac4f4d32ad89c66c34d02483,
title = "Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models",
abstract = "We explored whether the combination of lurbinectedin (PM01183) with the antimetabolite gemcitabine could result in a synergistic antitumor effect in pancreatic ductal adenocarcinoma (PDA) mouse models. We also studied the contribution of lurbinectedin to this synergism. This drug presents a dual pharmacological effect that contributes to its in vivo antitumor activity: (i) specific binding to DNA minor grooves, inhibiting active transcription and DNA repair; and (ii) specific depletion of tumor-associated macrophages (TAMs). We evaluated the in vivo antitumor activity of lurbinectedin and gemcitabine as single agents and in combination in SW-1990 and MIA PaCa-2 cell-line xenografts and in patient-derived PDA models (AVATAR). Lurbinectedin-gemcitabine combination induced a synergistic effect on both MIA PaCa-2 [combination index (CI)=0.66] and SW-1990 (CI=0.80) tumor xenografts. It also induced complete tumor remissions in four out of six patient-derived PDA xenografts. This synergism was associated with enhanced DNA damage (anti-γ- H2AX), cell cycle blockage, caspase-3 activation and apoptosis. In addition to the enhanced DNA damage, which is aconsequence of the interaction of the two drugs with the DNA, lurbinectedin induced TAM depletion leading to cytidine deaminase (CDA) downregulation in PDA tumors. This effect could, in turn, induce an increase of gemcitabine-mediated DNA damage that was especially relevant in high-density TAM tumors. These results show that lurbinectedin can be used to develop 'molecularly targeted' combination strategies.",
keywords = "Gemcitabine, Lurbinectedin, PDA mouse models, Synergism, Tumor-associated macrophage depletion",
author = "C{\'e}spedes, {Mar{\'i}a Virtudes} and Guill{\'e}n, {Mar{\'i}a Jos{\'e}} and L{\'o}pez-Casas, {Pedro Pablo} and Francesca Sarno and Alberto Gallardo and Patricia {\'A}lamo and Carmen Cuevas and Manuel Hidalgo and Galmarini, {Carlos Mar{\'i}a} and Paola Allavena and Pablo Avil{\'e}s and Ram{\'o}n Mangues",
year = "2016",
month = "12",
day = "1",
doi = "10.1242/dmm.026369",
language = "English",
volume = "9",
pages = "1461--1471",
journal = "DMM Disease Models and Mechanisms",
issn = "1754-8403",
publisher = "Company of Biologists Ltd",
number = "12",

}

TY - JOUR

T1 - Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models

AU - Céspedes, María Virtudes

AU - Guillén, María José

AU - López-Casas, Pedro Pablo

AU - Sarno, Francesca

AU - Gallardo, Alberto

AU - Álamo, Patricia

AU - Cuevas, Carmen

AU - Hidalgo, Manuel

AU - Galmarini, Carlos María

AU - Allavena, Paola

AU - Avilés, Pablo

AU - Mangues, Ramón

PY - 2016/12/1

Y1 - 2016/12/1

N2 - We explored whether the combination of lurbinectedin (PM01183) with the antimetabolite gemcitabine could result in a synergistic antitumor effect in pancreatic ductal adenocarcinoma (PDA) mouse models. We also studied the contribution of lurbinectedin to this synergism. This drug presents a dual pharmacological effect that contributes to its in vivo antitumor activity: (i) specific binding to DNA minor grooves, inhibiting active transcription and DNA repair; and (ii) specific depletion of tumor-associated macrophages (TAMs). We evaluated the in vivo antitumor activity of lurbinectedin and gemcitabine as single agents and in combination in SW-1990 and MIA PaCa-2 cell-line xenografts and in patient-derived PDA models (AVATAR). Lurbinectedin-gemcitabine combination induced a synergistic effect on both MIA PaCa-2 [combination index (CI)=0.66] and SW-1990 (CI=0.80) tumor xenografts. It also induced complete tumor remissions in four out of six patient-derived PDA xenografts. This synergism was associated with enhanced DNA damage (anti-γ- H2AX), cell cycle blockage, caspase-3 activation and apoptosis. In addition to the enhanced DNA damage, which is aconsequence of the interaction of the two drugs with the DNA, lurbinectedin induced TAM depletion leading to cytidine deaminase (CDA) downregulation in PDA tumors. This effect could, in turn, induce an increase of gemcitabine-mediated DNA damage that was especially relevant in high-density TAM tumors. These results show that lurbinectedin can be used to develop 'molecularly targeted' combination strategies.

AB - We explored whether the combination of lurbinectedin (PM01183) with the antimetabolite gemcitabine could result in a synergistic antitumor effect in pancreatic ductal adenocarcinoma (PDA) mouse models. We also studied the contribution of lurbinectedin to this synergism. This drug presents a dual pharmacological effect that contributes to its in vivo antitumor activity: (i) specific binding to DNA minor grooves, inhibiting active transcription and DNA repair; and (ii) specific depletion of tumor-associated macrophages (TAMs). We evaluated the in vivo antitumor activity of lurbinectedin and gemcitabine as single agents and in combination in SW-1990 and MIA PaCa-2 cell-line xenografts and in patient-derived PDA models (AVATAR). Lurbinectedin-gemcitabine combination induced a synergistic effect on both MIA PaCa-2 [combination index (CI)=0.66] and SW-1990 (CI=0.80) tumor xenografts. It also induced complete tumor remissions in four out of six patient-derived PDA xenografts. This synergism was associated with enhanced DNA damage (anti-γ- H2AX), cell cycle blockage, caspase-3 activation and apoptosis. In addition to the enhanced DNA damage, which is aconsequence of the interaction of the two drugs with the DNA, lurbinectedin induced TAM depletion leading to cytidine deaminase (CDA) downregulation in PDA tumors. This effect could, in turn, induce an increase of gemcitabine-mediated DNA damage that was especially relevant in high-density TAM tumors. These results show that lurbinectedin can be used to develop 'molecularly targeted' combination strategies.

KW - Gemcitabine

KW - Lurbinectedin

KW - PDA mouse models

KW - Synergism

KW - Tumor-associated macrophage depletion

UR - http://www.scopus.com/inward/record.url?scp=85008330507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008330507&partnerID=8YFLogxK

U2 - 10.1242/dmm.026369

DO - 10.1242/dmm.026369

M3 - Article

VL - 9

SP - 1461

EP - 1471

JO - DMM Disease Models and Mechanisms

JF - DMM Disease Models and Mechanisms

SN - 1754-8403

IS - 12

ER -